About: Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach
Creator	Cassone, Antonio Ascione, Alessandro Carattoli, Alessandra Cianfriglia, Maurizio Di Bonito, Paola Flego, Michela Grasso, Felicia Zamboni, Silvia
topic	covid:d6ea8e153027d428bc443df40d70bfa2134a2deb#this
source	Medline; PMC
abstract	BACKGROUND: Severe acute respiratory syndrome (SARS)-CoV is a newly emerging virus that causes SARS with high mortality rate in infected people. Successful control of the global SARS epidemic will require rapid and sensitive diagnostic tests to monitor its spread, as well as, the development of vaccines and new antiviral compounds including neutralizing antibodies that effectively prevent or treat this disease. METHODS: The human synthetic single-chain fragment variable (scFv) ETH-2 phage antibody library was used for the isolation of scFvs against the nucleocapsid (N) protein of SARS-CoV using a bio panning-based strategy. The selected scFvs were characterized under genetics-molecular aspects and for SARS-CoV N protein detection in ELISA, western blotting and immunocytochemistry. RESULTS: Human scFv antibodies to N protein of SARS-CoV can be easily isolated by selecting the ETH-2 phage library on immunotubes coated with antigen. These in vitro selected human scFvs specifically recognize in ELISA and western blotting studies distinct epitopes in N protein domains and detect in immunohistochemistry investigations SARS-CoV particles in infected Vero cells. CONCLUSION: The human scFv antibodies isolated and described in this study represent useful reagents for rapid detection of N SARS-CoV protein and SARS virus particles in infected target cells.
has issue date	2005-09-19(xsd:dateTime)
bibo:doi	10.1186/1471-2334-5-73
bibo:pmid	16171519
has license	cc-by
sha1sum (hex)	d6ea8e153027d428bc443df40d70bfa2134a2deb
schema:url	https://doi.org/10.1186/1471-2334-5-73
resource representing a document's title	Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach
has PubMed Central identifier	PMC1261265
has PubMed identifier	16171519
schema:publication	BMC Infect Dis
resource representing a document's body	covid:d6ea8e153027d428bc443df40d70bfa2134a2deb#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/d6ea8e153027d428bc443df40d70bfa2134a2deb
is schema:about of	named entity 'phage display' named entity 'APPROACH' named entity 'GENERATION' named entity 'DISEASE' named entity 'EPIDEMIC' named entity 'CONTROL' named entity 'ANTIBODY' named entity 'HUMAN' named entity 'BMC' named entity 'EPITOPES' named entity 'SUCCESSFUL' named entity 'MONITOR' named entity 'PEOPLE' named entity 'NEUTRALIZING ANTIBODIES' named entity 'RAPID' named entity 'DISTINCT' named entity 'NUCLEOCAPSID' named entity 'SARS-COV PROTEIN' named entity 'INFECTIOUS DISEASES' named entity 'HIGH' named entity 'ANTIVIRAL' named entity 'PROTEIN ' named entity 'MORTALITY RATE' named entity 'NEW' named entity 'VACCINES' named entity 'CAUSES' named entity 'DEVELOPMENT' named entity 'SPREAD' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'PREVENT' named entity 'INCLUDING' named entity 'ITS' named entity 'SENSITIVE' named entity 'NEWLY' named entity 'PHAGE DISPLAY' named entity 'FRAGMENTS' named entity 'INFECTED' named entity 'IS A' named entity 'BACKGROUND' named entity 'TREAT' named entity 'VIRUS' named entity 'GLOBAL' named entity 'DIAGNOSTIC TESTS' named entity 'USING' named entity 'SARS' covid:arg/d6ea8e153027d428bc443df40d70bfa2134a2deb named entity 'mortality rate' named entity 'Background' named entity 'monitor' named entity 'high' named entity 'protein' named entity 'Severe acute respiratory syndrome' named entity 'mortality rate' named entity 'Infectious Diseases' named entity 'nucleocapsid' named entity 'western blot' named entity 'protein' named entity 'phage' named entity 'serum' named entity 'protein' named entity 'nucleocapsid' named entity 'amino acid' named entity 'scFv' named entity 'antigen' named entity 'scFvs' named entity 'mutagenesis' named entity 'scFv' named entity 'random mutagenesis' named entity 'inoculated' named entity 'protein' named entity '1 ml' named entity 'nucleocapsid'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software